🏆 Deal of the Week · CW 3/2025
Bioptimus raised USD 41 million in a Series A round; the post-money valuation was not disclosed. The round was backed by Cathay Innovation. The funding was announced in January 2025.
Bioptimus — key deal facts
| Company | Bioptimus |
| Founded | 2024 |
| Headquarters | Paris, France |
| Amount raised | USD 41m |
| Valuation | Valuation Remains Undisclosed |
| Round | Series A |
| Investors | Cathay Innovation |
| Sectors | Biotechnology |
Who invested in Bioptimus?
Cathay Innovation led the Series A investment in Bioptimus. Cathay Innovation is a global venture fund with a strong focus on deep-tech and life-science innovation across Europe, Asia, and North America, making it a strategically aligned backer for a Paris-based AI biotech building foundation models for biology.
What does Bioptimus do?
Bioptimus is a Paris-headquartered AI biotech company founded in 2024. It is developing what it describes as the first universal foundation model for biology, with current products including the histology model H-Optimus-1 and the multimodal model M-Optimus. The company was co-founded by Professor Jean-Philippe Vert, PhD — formerly Chief R&D Officer at Owkin and Research Lead at Google Brain — alongside other alumni of Google DeepMind and Owkin. Its models are already in active use by 12 of the top 20 global pharmaceutical companies for drug discovery, research, and clinical pipeline applications.
Bioptimus valuation & multiples
Explore the benchmarks: Series A.
Frequently asked questions
How much did Bioptimus raise in its Series A?
Bioptimus raised USD 41 million in its Series A round, announced in January 2025.
What is Bioptimus's valuation?
Bioptimus's valuation was not disclosed in connection with the Series A round.
Who invested in Bioptimus?
Cathay Innovation invested in Bioptimus's Series A round.
When was Bioptimus founded and where is it based?
Bioptimus was founded in 2024 and is headquartered in Paris, France.
Source: original announcement — read the full report.